4D Molecular Therapeutics develops genetic medicines for eye diseases and cystic fibrosis, based in Emeryville, California. FDMT reports earnings on Tue, Nov 10, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for FDMT are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in FDMT in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FDMT is in one of them and how their past FDMT trades turned out.
4D Molecular Therapeutics is a biotechnology company that develops genetic medicines. Its product candidates use modified adeno-associated virus vectors, which are designed to carry therapeutic genes to target tissues. Its lead candidate is aimed at wet age-related macular degeneration and diabetic macular edema, two eye diseases, and is designed to be given by injection in a doctor's office. The company is also developing a treatment for lung disease in people with cystic fibrosis. It is based in Emeryville, California, and its intended customers are patients, eye and lung specialists, and healthcare payers.
